US Stock Insider Trading | Sarepta Discloses 2 Insider Transactions on March 2

2026-03-10 11:09:48

Abstract generation in progress

On March 2, 2026, Sarepta (SRPT) disclosed two insider transactions. Executive Estepan Ian Michael purchased 5,381 shares on February 26, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	Estepan Ian Michael	February 26, 2026	Buy	7,450	13.71	$102,100
January 29, 2026	Director	BEHRENS M KATHLEEN	January 27, 2026	Sell	6,494	22.17	$144,000
January 29, 2026	Director	Nicaise Claude	January 29, 2026	Sell	6,780	21.23	$143,900
January 29, 2026	Director	BEHRENS M KATHLEEN, Nicaise Claude	January 29, 2026	Buy	21,000	13.71	$287,900
December 18, 2025	Executive	Estepan Ian Michael	December 16, 2025	Sell	13,200	22.31	$294,200
December 10, 2025	Executive	Wong Ryan Ho-Yan	December 1, 2025	Sell	158	20.96	$3,312
December 2, 2025	Executive	Rothfuss Cristin	November 28, 2025	Sell	229	21.12	$4,836
November 19, 2025	Executive	Rodino-Klapac Louise	November 17, 2025	Sell	4,582	18.42	$84,400
May 19, 2025	Director	Barry Richard	May 16, 2025	Buy	12,400	32.63	$403,000
May 15, 2025	Director	Barry Richard	May 13, 2025	Buy	10,500	13.71	$144,000

[Company Profile]

Sarepta Therapeutics, Inc. was incorporated in Oregon on July 22, 1980. The company is a commercial-stage biopharmaceutical company focused on discovering and developing unique RNA-targeted therapies, gene therapies, and other gene-based treatments for rare diseases. Using their proprietary, highly differentiated, and innovative technologies, and through collaborations with strategic partners, the company has developed multiple approved products for the treatment of Duchenne Muscular Dystrophy and is developing potential candidate therapies for a broad range of diseases and disorders, including Duchenne, limb-girdle muscular dystrophy, and other neuromuscular and central nervous system-related conditions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.